Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2022-06-09 Annual Report
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于上海证券交易所对公司2021年年度报告的信息披露监管工作函的回复公告
Annual Report Classification · 95% confidence The document is a detailed reply announcement from 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) addressing regulatory inquiries from the Shanghai Stock Exchange regarding the company's 2021 Annual Report. It contains extensive quantitative analysis of sales revenue, gross profit, product categories, customer details, and bad debt provisions. The document includes management's explanations and auditor's opinions on the financial data and disclosures. The content is focused on clarifying and supplementing the disclosures made in the 2021 Annual Report, including detailed financial and operational data. The document length is substantial (15,000 characters), and it is not merely an announcement of a report but contains detailed financial and operational analysis. Therefore, it is best classified as an Annual Report (10-K) or a closely related detailed financial report. Given the context and the nature of the document as a reply to regulatory inquiries about the annual report, it aligns most closely with the Annual Report (10-K) category rather than a simple Regulatory Filing or Report Publication Announcement. FY 2021
2022-06-09 Chinese
北京兴华会计师事务所（特殊普通合伙）关于上海证券交易所《关于哈药集团股份有限公司2021年年度报告的信息披露监管工作函》的回复
Regulatory Filings
2022-06-09 Chinese
哈药集团股份有限公司九届二十六次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) regarding the 26th meeting of the 9th board of directors. It includes decisions on the nomination of a new director, amendments to the company bylaws due to changes in registered capital and shares, and the scheduling of the 2021 annual general meeting. The document is a formal announcement of board decisions and upcoming shareholder meeting details, not a full annual report, audit report, or financial statement. It does not contain financial data or detailed management discussion. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related board resolutions.
2022-06-06 Chinese
哈药集团股份有限公司关于修改《公司章程》的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors of 哈药集团股份有限公司 regarding amendments to the company's Articles of Association (公司章程) due to changes in registered capital and total shares. It details the approval of these amendments by the board and mentions that the changes require shareholder approval at a general meeting. The document is a formal announcement of corporate governance changes related to capital structure and company bylaws, not a full report or financial statement. It does not contain financial results, audit information, or detailed management discussion. The content fits best under Board/Management Information (MANG) as it concerns board resolutions and governance changes.
2022-06-06 Chinese
哈药集团股份有限公司独立董事关于公司九届二十六次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of 哈药集团股份有限公司 regarding the nomination of a director candidate for the company's ninth board. It discusses the qualifications and compliance of the candidate with relevant laws and company regulations. This is a board/management related announcement about changes or nominations in the company's board of directors. The document is short (449 characters) and focused on board matters, not a full report or financial data. Therefore, it fits the category of Board/Management Information (MANG).
2022-06-06 Chinese
哈药集团股份有限公司关于公司董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, specifically mentioning the resignation of Mr. Huang Rongkai from the board and nomination committee. It does not contain financial data, audit information, or any report content. The focus is on a change in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and clearly an announcement of management change.
2022-06-06 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.